Latest News and Press Releases

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Subscription to Raise $25m Oxford, UK, and Cambridge, MA, US, 8 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a...

Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Result of General Meeting Oxford, UK, and Cambridge, MA, US, 4 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...

THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR...

Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Therapeutics Announces Departure of Chief Financial Officer Oxford, UK, and Cambridge, MA, US, 17 December 2018 - Summit Therapeutics plc...

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 and Operational Progress ...

Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018 Oxford,...

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the...